Comparing two ways to give Phesgo to reduce injection pain
Part of Cancer, Pain, Skin clinical trials.
This study compares two ways of giving a large-volume injection of Phesgo (a targeted breast cancer treatment) to see which one is less painful. Half of the injections use a special device with a steady speed; the other half are done by hand. You will receive both methods, and you'll rate your pain, helping find a more comfortable way to give the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70 with HER2-positive breast cancer.
- You have already had at least one injection of Phesgo (a targeted therapy) and have at least 3 more injections planned.
- You have not had an allergic reaction to Phesgo in the past.
- You have not used any pain medication, patches, or pumps within 3 days before your injection.
- You have normal activity levels, no limb paralysis, and can clearly describe your feelings.
- You do not have skin problems at the injection site and are not taking other pain relievers regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests simple, non-drug methods to reduce pain and fear during hormone injections for breast cancer. These methods might help make the injection more comfortable and less anxiety-provoking.
This trial compares giving one injection versus several injections of a numbing medicine around the spine to control pain after breast cancer surgery. It may help reduce pain and the need for strong painkillers after the procedure.
This trial tests two different numbing injections to see which one works better for pain after breast cancer surgery. If you are having a mastectomy, you may be able to join and help find a better way to manage pain.
This trial tests a new medication (HLX319) against an approved treatment (Phesgo) given before surgery for HER2-positive breast cancer. The goal is to see if the new drug works just as well and is safe, potentially offering another option to help shrink tumors before surgery.
This Phase 2 trial tests whether PG2 injections can safely reduce moderate to severe fatigue in people receiving chemotherapy for locally advanced, recurrent, or metastatic breast cancer. If you qualify, you may be asked to complete questionnaires and follow study plans for about 8 weeks.
This study checks if giving larger volumes of liquid under the skin (subcutaneous injection) at different speeds is comfortable and acceptable to healthy people. It aims to see how the body reacts to help make future injections more comfortable for patients.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.